Axonics (AXNX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AXNX Axonics

Watchlist

70.370
+0.070+0.10%

Close Nov 1 16:00 ET

70.370
0.0000.00%

Post 20:01 ET

3.60BMarket Cap-3518500P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Boston Scientific Still Expects Axonics Deal to Close This Year, Posts Street-beating Q3
MassDeviceOct 23 08:13 ET
Catalyst Watch: Earnings Blitz, Fed Speakers, and Notable Healthcare Conferences
Seeking AlphaOct 18 15:00 ET
Axonics Gains After Boston Scientific Says It Will End Use of Coaptite on Nov. 1
Seeking AlphaOct 9 14:09 ET
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
Zacks Sep 27 09:35 ET
Express News | Axonics Inc - Expects to Commence Sales of R20 to Australian Customers in November
ReutersSep 26 06:01 ET
Express News | Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable Snm System in Australia
ReutersSep 26 06:00 ET

Comments

Moomoo AI

Mar 1 13:55

Analysts' consensus shows Axonics performing as expected, with no major estimate changes post recent results. Despite a predicted slowdown in revenue growth, Axonics is still expected to outpace the wider industry.

Analysts Have Made A Financial Statement On Axonics, Inc.'s (NASDAQ:AXNX) Full-Year Report

Moomoo AI

Feb 12 08:44

Axonics' consistent revenue growth, despite last year's lack of profit, has led to a 33% annual increase in share price over the past five years, making it a potential investment opportunity.

Investing in Axonics (NASDAQ:AXNX) Five Years Ago Would Have Delivered You a 313% Gain

Moomoo AI

Jan 8 06:25

Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.

Press Release: Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Moomoo AI

Jan 3 20:12

Investors believe in Axonics' potential for future revenue growth, supporting higher stock prices despite a high P/S ratio. They discount the chance of a revenue decrease, but risks and other factors must also be considered.

Axonics, Inc.'s (NASDAQ:AXNX) P/S Still Appears To Be Reasonable

Moomoo AI

Nov 7, 2023 05:18

Axonics' strong revenue growth may be driving its stock performance and could be attractive for growth investors. The recent sell-off may open up investment opportunities if long-term growth signs are positive.

Axonics (NASDAQ:AXNX) Delivers Shareholders Strong 29% CAGR Over 5 Years, Surging 8.0% in the Last Week Alone

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

AXNX Axonics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target